Vinge advises Aspo, listed on Nasdaq Helsinki, in the transaction whereby Aspo's subsidiary Telko expands its chemicals business in Sweden by acquiring Swed Handling, a leading Swedish chemical distributor, from TeRa Invest. As part of the transaction, Aspo’s subsidiary Leipurin expands its food industry business in Sweden, via the technical food ingredient distributor Kebelco, which is a subsidiary of Swed Handling. The closing of the transaction is subject to customary regulatory approvals.

The enterprise value of the transaction is SEK 500 million, with potential for an additional earnout of up to SEK 130 million. Up to SEK 100 million of the purchase price can be paid in Aspo shares.

Aspo is a Finnish conglomerate that specializes in demanding B-to-B customers. Aspo creates value by owning and developing business operations sustainably and in the long term. Aspo has businesses in 16 different countries, and it employs a total of approximately 700 professionals.

Read the client’s press release here.

Vinge’s team mainly consisted of Jonas Johansson, Linus Adolfsson, Tim Axell (M&A), Karl-Gustaw Tobola (Banking and Finance), Mario Saad (Corporate Commercial), Ebba Svenburg, Jonna Skog (Employment) Johan Cederblad, Lina Österberg (Environment), Elis Almark, Carla Zachariasson (IT & GDPR), Karolina Cohrs (Real Estate), Daniel Wendelsson, Sebastian Örndahl, Dagne Sabockis, Hilda Ivarsson (FDI, EU, Competition and Regulatory) and Emma Emsjö (Transaction Support Coordinator).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026